-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Spero Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2016 to 2024.
- Spero Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2023 was $0.000, a 100% decline year-over-year.
- Spero Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $0.000, a 100% decline from 2023.
- Spero Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $221K.
- Spero Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$29.6M, a 135% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)